Safety, Tolerability And Ldl-C Reduction With A Novel Anti-Pcsk9 Recombinant Fusion Protein (Lib003): Results Of A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study
暂无分享,去创建一个
E. Stein | D. Kereiakes | H. Bays | Rong Zhou | P. Toth | T. Turner | M. B. Butcher | P. Magnu